Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

Sponsor
Fudan University
Study ID
NCT04425187
Phase
PHASE2
Status
Unknown

Conditions

  • PFS

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.

Key Dates

First listed
Jun 11, 2020
Start date
Jun 8, 2020
Status verified
Jun 2020
Primary completion
Dec 31, 2021
Completion
Dec 31, 2022

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: gefitinib
  • Experimental: gefitinib&bevacizumab

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months ]

Central Contacts